SCHEMBL910132

SCHEMBL910132

CC(=O)c1cc(C)cc(C(C)=O)c1O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
POLB P06746 2/20 0.47
NSD2 O96028 1/20 0.47
MAPT P10636 1/20 0.47
MCL1 Q07820 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.46
SELL P14151 1/20 0.43
SELP P16109 1/20 0.43
SELE P16581 1/20 0.43
CSNK2A1 P68400 1/20 0.41
ERN1 O75460 1/20 0.41
HTT P42858 1/20 0.40
ALDH1A1 P00352 3/20 0.39
TPMT P51580 1/20 0.39
CA5A P35218 1/20 0.39
HCAR1 Q9BXC0 1/20 0.38
GPR35 Q9HC97 1/20 0.38
ACHE P22303 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6175983 0.91 CSNK2A1 (0.50) KDM4EMEN1KMT2APOLBNSD2
SCHEMBL3659922 0.88 SELL (0.56) KDM4EMEN1KMT2APOLBNSD2
SCHEMBL471443 0.88 KDM4E (0.46) KDM4EMEN1KMT2APOLBNSD2
SCHEMBL3661233 0.84 KDM4E (0.54) KDM4EMEN1KMT2APOLBNSD2
SCHEMBL909607 0.84 PLAU (0.50) KDM4EMEN1KMT2APOLBNSD2
SCHEMBL11712068 0.84 AKR1C2 (0.46) KDM4EMEN1KMT2APOLBNSD2
SCHEMBL14394630 0.82 APP (0.46) KDM4EMEN1KMT2APOLBNSD2
SCHEMBL6299118 0.82 GAA (0.51) KDM4EKMT2APOLBMAPTALDH1A1
SCHEMBL3659084 0.81 LMNA (0.55) KDM4EMEN1KMT2APOLBNSD2
SCHEMBL17500078 0.81 SMN1; SMN2 (0.63) KDM4EMEN1KMT2APOLBNSD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118647934-A Laminate, method for producing laminate, hollow structure, and electronic component 东丽株式会社 2024-09-13 CN disclosed
CN-106631730-B Preparation method and application of fluorescent sensing material based on bis-Schiff base 江苏大学 2020-06-26 CN disclosed
US-7872011-B2 Inhibition of phosphoinositide 3-kinase β ASTRAZENECA AB (SE) 2011-01-18 US disclosed
US-7872011-B2 Inhibition of phosphoinositide 3-kinase β ASTRAZENECA AB (SE) 2011-01-18 US disclosed
US-7872011-B2 Inhibition of phosphoinositide 3-kinase β ASTRAZENECA AB (SE) 2011-01-18 US disclosed
US-20100129698-A1 ELECTRODE CATALYST FOR FUEL CELL NATIONAL INSTITUTE OF ADVANCED SCIENCE AND TECHNOLOGY (JP) 2010-05-27 US disclosed
US-20100129698-A1 ELECTRODE CATALYST FOR FUEL CELL NATIONAL INSTITUTE OF ADVANCED SCIENCE AND TECHNOLOGY (JP) 2010-05-27 US disclosed
US-20100129698-A1 ELECTRODE CATALYST FOR FUEL CELL NATIONAL INSTITUTE OF ADVANCED SCIENCE AND TECHNOLOGY (JP) 2010-05-27 US disclosed
US-20090318681-A1 METAL COMPLEX, AND USE THEREOF SUMITOMO CHEMICAL COMPANY LIMITED (JP) 2009-12-24 US disclosed
US-20090318681-A1 METAL COMPLEX, AND USE THEREOF SUMITOMO CHEMICAL COMPANY LIMITED (JP) 2009-12-24 US disclosed
EP-2133145-A1 ELECTRODE CATALYST FOR FUEL CELL Sumitomo Chemical Company, Limited (JP) 2009-12-16 EP disclosed
US-7598377-B2 (+-)-7-Methyl-2-morpholin-4-yl-9-(1-phenylaminoethyl)-pyrido[1,2-a]pyrimidin-4-one, for example; selective inhibitors of phosphoinositide (PI) 3-kinase beta for use in anti-thrombotic therapy ASTRAZENECA AB (SE) 2009-10-06 US disclosed
US-7598377-B2 (+-)-7-Methyl-2-morpholin-4-yl-9-(1-phenylaminoethyl)-pyrido[1,2-a]pyrimidin-4-one, for example; selective inhibitors of phosphoinositide (PI) 3-kinase beta for use in anti-thrombotic therapy ASTRAZENECA AB (SE) 2009-10-06 US disclosed
US-7598377-B2 (+-)-7-Methyl-2-morpholin-4-yl-9-(1-phenylaminoethyl)-pyrido[1,2-a]pyrimidin-4-one, for example; selective inhibitors of phosphoinositide (PI) 3-kinase beta for use in anti-thrombotic therapy ASTRAZENECA AB (SE) 2009-10-06 US disclosed
US-20080319021-A1 Inhibition Of Phosphoinositide 3-Kinase Beta KINACIA PTY. LTD. (AU) 2008-12-25 US disclosed
US-20080319021-A1 Inhibition Of Phosphoinositide 3-Kinase Beta KINACIA PTY. LTD. (AU) 2008-12-25 US disclosed
US-20080319021-A1 Inhibition Of Phosphoinositide 3-Kinase Beta KINACIA PTY. LTD. (AU) 2008-12-25 US disclosed
US-20060276470-A1 (+-)-7-Methyl-2-morpholin-4-yl-9-(1-phenylaminoethyl)-pyrido[1,2-a]pyrimidin-4-one, for example; selective inhibitors of phosphoinositide (PI) 3-kinase beta for use in anti-thrombotic therapy ASTRAZENECA AB (SE) 2006-12-07 US disclosed
EP-1537102-A1 INHIBITION OF PHSPHOINOSTIDE 3-DINASE BETA Kinacia Pty Ltd. (AU) 2005-06-08 EP disclosed
WO-2004016607-A1 INHIBITION OF PHOSPHOINOSITIDE 3-KINASE BETA KINACIA PTY LTD. (AU) 2004-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080319021-A1 Inhibition Of Phosphoinositide 3-Kinase Beta PI4KB, PI4KA, PI4K2B KDM4E 2002/4885MEN1 2560/4885KMT2A 3584/4885
US-20060276470-A1 (+-)-7-Methyl-2-morpholin-4-yl-9-(1-phenylaminoethyl)-pyrido[1,2-a]pyrimidin-4-one, for example; selective inhibitors of phosphoinositide (PI) 3-kinase beta for use in anti-thrombotic therapy PI4KA, PI4KB, PI4K2B KDM4E 1008/4885MEN1 2649/4885KMT2A 2732/4885
US-20090318681-A1 METAL COMPLEX, AND USE THEREOF MT-CO1, CYC1, ACAD9 KDM4E 4791/4885MEN1 762/4885KMT2A 3989/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.